Management of BRAF-Mutated Non-Small Cell Lung Cancer
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, University of California, San Diego, California, discussed developments and advances in the management of BRAF-mutated non-small cell lung cancer.
Transcript:
I am Dr Lyudmila Bazhenova, Professor of Medicine and Thoracic Medical Oncologist from University of California San Diego, and I'm here at the Great Debates & Updates in Lung Cancer Conference in New York in September of 2023.
My topic to discuss today is management of BRAF-mutant non-small cell lung cancer. I will be discussing the fact that there are 3 types of BRAF mutations, Class 1, 2, and 3. The most common mutation in lung cancer is class 1 mutation. Overall, BRAF mutations are found in approximately 45% patients with lung cancer.
The current standard of care for this patient population is a dual drug therapy, which is dabrafenib and trametinib, which results in approximately 60% response rate and reasonably long progression-free survival. Unfortunately, resistance will eventually develop to patients with those combinations, and we are learning how to correctly manage the resistance.
There are several interesting clinical trials in that space, which I will be highlighting, primarily the drug from Kinnate Therapeutics, which has been developed for Class 2 BRAF mutations, which have some interesting preliminary efficacy.
Source:
Bazhenova L. BRAF Mutations: Identifying and Addressing a Rare Oncogenic Driver. Presented at Great Debates & Updates in Lung Cancer; September 21-23; New York, NY.
